Advancing Gene Therapy Research for Hemophilia A at MCW
Kristi Castello, Division Administrator III at the Medical College of Wisconsin, reposted from Medical College of Wisconsin on LinkedIn:
Quoting Medical College of Wisconsin‘s post:
”For people with hemophilia A, a simple cut or bump can cause excessive bleeding or bruising. While treatments exist to replace this protein, patients may form antibodies to the current therapies.
For more than two decades, MCW’s David A. Wilcox, PhD has worked with colleagues to develop a new gene therapy that could transform how patients with the disease are treated.
The team has completed preliminary studies of a Phase 1 clinical trial at MCW, ran by MCW’s Dr. Mary Eapen, with a gene therapy that genetically-modifies a patient’s own bone marrow cells to make a blood clotting factor.
Learn more:”
Stay updated with Hemostasis Today.
-
Jan 26, 2026, 04:59Abdul Mannan: BDUC – 4 Letters That Make Many Haematologists Uncomfortable
-
Jan 26, 2026, 04:51Manoj Kumar Singh: Power In Me Foundation Celebrates 2026 as Year Of Rare
-
Jan 26, 2026, 04:40Heghine Khachatryan: Did You Know VWD Comprises 3 Main Types?
-
Jan 25, 2026, 15:57Céline Chapelle Shares Clinical Predictors From the API-CAT Trial
-
Jan 25, 2026, 15:42Francesco Lo Monaco on Heart Disease Starting Quiet While Your Labs Speak First
-
Jan 25, 2026, 15:25Muhammad Ibrahim on Efficacy and Safety of Extended DOACs Use in VTE
-
Jan 25, 2026, 15:08Tushar Pandey on Managing Thrombotic Thrombocytopenic Purpura
-
Jan 25, 2026, 14:55Carolina Contreras Cuevas Shares a Nationwide Study on VTE in PAD
-
Jan 25, 2026, 14:40Jeannie Devereaux Links PRP and Physical Therapy